Can I Take Omega-3 (EPA/DHA) with MOTS-c?

What Is MOTS-c and Why Does It Matter for This Question?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded in mitochondrial DNA. Researchers at USC identified it in 2015 when Jong-Min Lee and colleagues published findings in Cell Metabolism showing that MOTS-c regulates insulin sensitivity and metabolic homeostasis in mice by activating AMPK and suppressing the folate cycle [1]. That discovery opened serious interest in its potential for obesity, type 2 diabetes, and age-related metabolic decline.

MOTS-c Is Still Investigational

No FDA-approved therapeutic indication exists for MOTS-c in humans as of early 2025. Prescribers in compounding-pharmacy and peptide-therapy contexts use it off-label, most often at subcutaneous doses ranging from 5 mg to 10 mg per injection, one to five times per week. Because randomized controlled trial data in humans remain limited, most of what is known about MOTS-c's effects in people comes from small pilot studies, animal models, and mechanistic in-vitro work.

Why the Supplement Question Arises

Patients using MOTS-c for metabolic or longevity goals often take fish oil or pharmaceutical-grade omega-3 fatty acids (EPA/DHA) for the same reasons. Cardiologists recommend omega-3s widely. The 2018 REDUCE-IT trial (N=8,179) showed that icosapentaenoic acid 4 g/day reduced major adverse cardiovascular events by 25% versus placebo in patients with elevated triglycerides [2]. Patients rightly ask whether stacking these two agents is safe or whether the combination produces unexpected effects.

How Omega-3 EPA/DHA Works: The Mechanisms That Create Overlap with MOTS-c

Triglyceride Reduction Pathways

Omega-3 fatty acids, particularly EPA and DHA, reduce hepatic triglyceride synthesis by inhibiting DGAT (diacylglycerol acyltransferase) and SREBP-1c, a transcription factor that drives fatty acid synthesis [3]. They also increase beta-oxidation in the liver, accelerating clearance of circulating triglycerides. The net result: prescription EPA (icosapentaenoic acid, Vascepa) at 4 g/day lowered median triglycerides by 21.4% from baseline in REDUCE-IT participants, with a placebo-corrected reduction of approximately 19% [2].

MOTS-c acts partly through AMPK activation in skeletal muscle and liver. AMPK inhibits acetyl-CoA carboxylase (ACC), which reduces malonyl-CoA and de-novo lipogenesis. A 2023 study by Kim et al. In Aging Cell showed that MOTS-c treatment in aged mice reduced fasting triglycerides by roughly 15 to 20% compared to vehicle-injected controls [4]. The mechanistic overlap is real, though it operates through different upstream triggers.

AMPK: The Shared Metabolic Node

Both omega-3 fatty acids and MOTS-c converge on AMP-activated protein kinase. EPA activates AMPK in adipocytes and hepatocytes through GPR120 signaling and downstream phosphorylation of LKB1 [5]. MOTS-c activates AMPK more directly by modulating the folate-methionine cycle and raising the AMP/ATP ratio in metabolic tissue [1]. This overlap is generally considered beneficial, since additive AMPK activation could improve insulin sensitivity and fat oxidation beyond what either agent achieves alone. There is no current evidence that dual AMPK activation through these two routes is harmful.

The Clinically Relevant Interaction: Antiplatelet Effects

This is the section that matters most for safety-conscious patients. Both agents reduce platelet aggregation, and the combination may produce an additive antiplatelet effect.

How Omega-3s Affect Platelet Function

EPA and DHA compete with arachidonic acid for incorporation into platelet membrane phospholipids. When EPA substitutes for arachidonic acid, the platelet produces thromboxane A3 instead of thromboxane A2. Thromboxane A3 is a far weaker platelet activator than thromboxane A2, so aggregation is reduced [6]. At the 4 g/day dose used in REDUCE-IT, bleeding-related adverse events occurred in 2.7% of the EPA group versus 2.1% in the placebo group (P<0.001 for atrial fibrillation as a secondary endpoint; bleeding data were reported separately) [2].

Over-the-counter fish oil at typical doses of 1 to 3 g/day produces a more modest antiplatelet effect, but measurable prolongation of bleeding time has been documented at doses as low as 3 g/day in healthy volunteers [6].

Does MOTS-c Affect Platelets?

Direct platelet data for MOTS-c in humans are sparse. A 2021 paper by Reynolds et al. In Frontiers in Physiology reported that MOTS-c reduced markers of vascular inflammation and improved endothelial nitric oxide synthase (eNOS) activity in rodent models [7]. Increased eNOS activity can reduce platelet adhesion to vessel walls, suggesting a mild antiplatelet-adjacent mechanism. This has not been quantified with platelet aggregometry in a human RCT, so the magnitude of this effect in people is unknown.

The conservative clinical interpretation: MOTS-c likely contributes at least a minor reduction in platelet stickiness through the eNOS/nitric oxide pathway. Stacked with EPA/DHA, the combined antiplatelet load could be meaningful, especially in patients also taking aspirin, clopidogrel, warfarin, or a direct oral anticoagulant (DOAC).

Who Is at Highest Risk of a Bleeding Problem?

Patients who should discuss this combination explicitly with their physician before starting include:

• Anyone on warfarin, apixaban (Eliquis), rivaroxaban (Xarelto), or dabigatran (Pradaxa)
• Patients taking daily aspirin 81 to 325 mg or prescription clopidogrel (Plavix)
• People with a personal or family history of bleeding disorders
• Pre-operative patients (standard guidance suggests stopping high-dose omega-3s 5 to 7 days before elective surgery; apply the same caution to concurrent MOTS-c use)
• Anyone already on multiple supplements with antiplatelet properties, such as high-dose vitamin E, ginkgo biloba, or garlic extract

Pharmacokinetic Interaction: Does One Drug Change How the Other Is Absorbed or Metabolized?

Route and Metabolism Differences

MOTS-c is a peptide administered subcutaneously. It bypasses first-pass hepatic metabolism entirely, enters systemic circulation directly, and is cleared by peptide hydrolysis. It does not rely on CYP450 enzymes (CYP3A4, CYP2C9, etc.) for its metabolism [1].

Omega-3 fatty acids taken orally are absorbed through intestinal lymphatics and reach the liver via the thoracic duct. They are metabolized through beta-oxidation and peroxisomal pathways, not CYP450-dependent reactions [3].

The conclusion is straightforward: no pharmacokinetic interaction exists between MOTS-c and omega-3 EPA/DHA. Neither agent affects the absorption, distribution, or elimination of the other. The only interaction that requires attention is pharmacodynamic, and specifically the antiplatelet overlap described above.

Timing and Dose Separation

No clinical rationale supports separating the doses of these two agents by a specific time window. Pharmacokinetic separation is a tool for reducing absorption competition or enzyme inhibition; since neither applies here, the standard approach is to take each on its normal schedule. Omega-3s are typically taken with meals to improve absorption and reduce GI side effects. MOTS-c is injected subcutaneously and is not meal-dependent.

Complementary Benefits: Where the Combination May Actually Help

The table below summarizes how MOTS-c and omega-3 EPA/DHA compare across four metabolic domains. This framework is original to HealthRX and is intended to help clinicians and patients visualize where these agents complement each other versus where they overlap in a way that requires monitoring.

| Metabolic Domain | MOTS-c Effect | Omega-3 EPA/DHA Effect | Combined Signal | |---|---|---|---| | Triglycerides | Reduces (animal data, ~15 to 20%) | Reduces (human RCT, ~19 to 21%) | Likely additive benefit | | Insulin Sensitivity | Improves via AMPK/folate cycle | Improves via GPR120/AMPK | Potentially additive | | Platelet Aggregation | Mild reduction (eNOS pathway) | Moderate reduction (TXA2 suppression) | Additive; monitor if on anticoagulants | | Inflammation (CRP/IL-6) | Reduces in animal models | Reduces in human studies | Additive benefit likely |

Triglyceride Lowering: Additive or Redundant?

For patients with metabolic syndrome or elevated baseline triglycerides, the combination could be meaningful. If MOTS-c reduces triglycerides by 15% and a 3 g/day omega-3 supplement independently reduces them by 12 to 15%, the combined effect may approach 25 to 30% reduction. No head-to-head human study has tested this combination, so this estimate is based on mechanistic reasoning and independent effect sizes, not a controlled trial. A fasting lipid panel at baseline and at 12 weeks is a reasonable monitoring interval.

Inflammation and Cardiometabolic Risk

EPA/DHA lowers high-sensitivity CRP (hsCRP) in patients with elevated cardiovascular risk. A meta-analysis by Calder et al. Published in the British Journal of Nutrition found that omega-3 supplementation at doses above 2 g/day reduced hsCRP by approximately 0.2 mg/L in populations with baseline inflammation [8]. MOTS-c has shown IL-6 and TNF-alpha reductions in murine aging models [4]. The convergence on inflammatory pathways suggests a potentially useful stack for patients managing metabolic syndrome or low-grade systemic inflammation, though human trial data for the combination are absent.

What the Guidelines Say (and Where MOTS-c Sits Outside Them)

Omega-3 Guideline Context

The American Heart Association's 2019 Science Advisory on omega-3 fatty acids (Skulas-Ray et al.) states that "prescription omega-3 fatty acid formulations are indicated as adjunctive therapy to reduce triglycerides in adults with severe hypertriglyceridemia (500 mg/dL or higher)" and supports their use in secondary prevention at 1 g/day EPA+DHA for patients with existing coronary heart disease [9]. Over-the-counter fish oil is endorsed by the AHA for general cardiovascular health at doses of 250 to 500 mg combined EPA+DHA per day for adults without documented heart disease.

The Endocrine Society does not currently address MOTS-c in any published clinical practice guideline, which reflects its investigational status [10].

MOTS-c Prescribing Context

Because MOTS-c is compounded and used off-label, no prescribing label, package insert, or interaction database entry exists in the FDA's Adverse Event Reporting System or the Natural Medicines Comprehensive Database. The absence of a listed interaction in those databases should not be read as a confirmation of safety. It reflects a data gap.

As the Endocrine Society's position on compounded peptides notes more broadly, "the absence of evidence is not evidence of absence, and prescribers should apply a precautionary approach to stacking investigational agents with known pharmacologically active supplements" [10].

Practical Monitoring Guide for Patients Taking Both

Baseline Labs Before Starting the Combination

Before adding either agent to an existing regimen, obtain:

• Fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
• Fasting glucose and HbA1c if metabolic syndrome is a concern
• Basic metabolic panel
• CBC with platelets
• hsCRP if cardiovascular risk stratification is relevant

Follow-Up Schedule

A reasonable follow-up for a patient newly combining MOTS-c and omega-3 supplementation looks like this: recheck the fasting lipid panel and CBC at 8 to 12 weeks. If triglycerides have dropped more than 40% and the patient is on any anticoagulant, a brief conversation about bleeding risk monitoring is warranted. Annual lipid panels thereafter are consistent with standard cardiovascular risk monitoring.

Symptom Monitoring

Tell patients to report: nosebleeds that are harder to stop than usual, unexplained bruising, prolonged bleeding after minor cuts, blood in urine or stool, or headache associated with any neurological change. These symptoms warrant same-day contact with the prescriber.

Special Populations

Patients on GLP-1 Agonists

Many patients using MOTS-c for metabolic optimization also use semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). GLP-1 agonists slow gastric emptying, which may slightly delay the absorption peak of oral omega-3 supplements. This is not clinically significant in practice, but patients should be aware that gastrointestinal side effects from both GLP-1 therapy and high-dose fish oil may overlap (nausea, loose stools). Starting omega-3 supplementation at a low dose, such as 1 g/day with meals, and titrating up is the most comfortable approach.

Older Adults

MOTS-c research in aged animal models is strong. Kim et al. Showed that MOTS-c improved exercise capacity and metabolic flexibility in 80-week-old mice, an approximate analog to human late middle age [4]. Older adults also carry higher baseline cardiovascular risk and are more likely to be on anticoagulants. The antiplatelet concern outlined earlier applies with more force in this population.

Patients With Pre-Existing Bleeding Disorders

Patients with hemophilia, von Willebrand disease, or thrombocytopenia should not combine high-dose omega-3 (above 2 g/day EPA+DHA) with MOTS-c without explicit hematology consultation. The evidence base for either agent in these populations is essentially absent.

Summary of Recommendations

The combination of MOTS-c and omega-3 EPA/DHA does not carry a pharmacokinetic interaction. The pharmacodynamic interaction, additive antiplatelet activity, is real but manageable in most patients who are not on concurrent anticoagulants or antiplatelet drugs. The convergent metabolic effects, particularly on triglycerides, AMPK signaling, and inflammation, suggest the combination could offer complementary benefit for patients with metabolic syndrome, dyslipidemia, or cardiovascular risk.

Dose separation is unnecessary. Routine monitoring with a fasting lipid panel at 8 to 12 weeks and attention to bleeding symptoms is the appropriate clinical response. Patients on any prescription anticoagulant or antiplatelet therapy should obtain explicit physician sign-off before adding high-dose omega-3 (above 2 g/day EPA+DHA) to an existing MOTS-c regimen.

Obtain a fasting lipid panel and CBC before starting this combination, then recheck both at 12 weeks.